Fri.Apr 19, 2024

article thumbnail

Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use

Fierce Pharma

Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. | Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured an FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations.

FDA 317
article thumbnail

Ilant Health Raises Extended Seed Round of $5.5M for Obesity Management Platform

MedCity News

Ilant Health extended its seed round from $3 million to $5.5 million. The company garnered interest from LifeX Ventures, Celtic House Asia Partners and Cornucopian Capital. The post Ilant Health Raises Extended Seed Round of $5.5M for Obesity Management Platform appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

'The Top Line': Winning formulas for the best biotech and drug names

Fierce Pharma

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. | This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness.

Pharma 264
article thumbnail

Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

PharmaVoice

Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

Doctors 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

FibroGen settles with former employees who it claimed stole trade secrets

Fierce Pharma

Nearly a year and a half after FibroGen slapped a pair of former employees with a lawsuit alleging trade secrets theft, both the plaintiffs and the defendants are walking away from the case little | Nearly a year and a half after FibroGen slapped a pair of former employees with a lawsuit alleging trade secrets theft, both the plaintiffs and the defendants are walking away from the case little worse for wear.

264
264
article thumbnail

Confronting the Digital Dilemma in Healthcare’s Quest for Innovation

MedCity News

The imperative to modernize healthcare communication methods extends beyond mere technological upgrades. Rather, it’s a fundamental necessity to enhance patient care, streamline healthcare delivery, and unlock the full potential of medical innovation. The post Confronting the Digital Dilemma in Healthcare’s Quest for Innovation appeared first on MedCity News.

More Trending

article thumbnail

Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer

MedCity News

The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation. The post Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer appeared first on MedCity News.

FDA 118
article thumbnail

Fierce Pharma Asia—Leqembi's cost to Medicare; Takeda's $1.2B-plus Kumquat deal; Fujifilm Diosynth's reorg

Fierce Pharma

Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an immuno-oncology deal potentially worth more than $1.2 billion. | Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an immuno-oncology deal potentially worth more than $1.2 billion.

Pharma 130
article thumbnail

FDA clears Roche’s Alecensa for adjuvant use in NSCLC

pharmaphorum

Roche's Alecenesa has become the first ALK inhibitor to be approved by the FDA for adjuvant use in early-stage, ALK+ NSCLC

FDA 115
article thumbnail

Emerging Mental Health Care Options for EDs in Crisis

MedCity News

Optimizing care journeys based on patient needs and using collaborative resources outside of the ED can result in effective and efficient behavioral care, regardless of volume. The post Emerging Mental Health Care Options for EDs in Crisis appeared first on MedCity News.

Patients 106
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Hyundai Bio plans trials of antiviral for dengue fever

pharmaphorum

Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever

111
111
article thumbnail

LogiPharma Europe 2024: Niklas Adamsson Discusses Ways to Improve Visibility and Risk Management for Cold Chain Shipping

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Environtainer, suggests how to improve visibility and risk management for cold chain shipping.

article thumbnail

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

pharmaphorum

Cerevel's first phase 3 trial of Parkinson's drug tavapadon is positive - good news for AbbVie which is trying to buy the biotech for $8.

105
105
article thumbnail

Protecting Health Data Without Harming Patients: Overcoming the Barriers That Limit Our Access to Our Personal Health Information

MedCity News

The availability of innovative technologies affords us the opportunity to chart a more patient-centric, efficient, and secure path to managing and leveraging PHI. The post Protecting Health Data Without Harming Patients: Overcoming the Barriers That Limit Our Access to Our Personal Health Information appeared first on MedCity News.

Patients 105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Pharma Pulse 4/19/24: The Real Cost of State Drug Importation Programs, Millions in Africa Will Miss HPV Shots After Merck Production Problem & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

How Are You Guiding Employers on Virtual Care Solutions Within Their Benefits Plan?

MedCity News

Attenton, healthcare benefit consultants: Take part in our survey and share some of the trends you are seeing among your clients. A full report of the findings will be available later this year. The post How Are You Guiding Employers on Virtual Care Solutions Within Their Benefits Plan? appeared first on MedCity News.

article thumbnail

Experimental AI predicts whether cancer drugs will work

pharmaphorum

Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer treatment

Patients 105
article thumbnail

Enhancing competitiveness of European life sciences

European Pharmaceutical Review

Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. Collaboration was highlighted by the Council as an essential factor to “close growth, productivity and innovation gaps between the Union and its international partners and main competitors… [therefore] policy action must be better put at the service of enhancing Europe’s economic, manufacturing, industrial and

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Personalization In Sales Leads To Increased Loyalty and Repeat Business

Integrity Solutions

Mastering the human side of selling is key to sales success, but what does phrase that mean exactly? At its essence, humanizing the sales experience is really about personalization. It’s about asking questions from a place of genuine curiosity, listening, fully absorbing what you’re hearing and then being willing and able to pivot in whatever direction the customer’s answers take us.

Sales 104
article thumbnail

Microbial burden assessment of solid pharmaceutical products

European Pharmaceutical Review

The “accurate, precise, and robust” data obtained via the dew point chilled mirror method, means it is an “outstanding” approach for quantifying water activity status in tablets and capsules, according to a paper published in RPS Pharmacy and Pharmacology Reports. It has value for direct assessment to determine microbiological bioburden , stated Prada-Ramírez et al.

article thumbnail

AskBio’s AB-1002 gene therapy receives FDA fast-track status

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at treating congestive heart failure (CHF).

article thumbnail

A Look at the Impact of Industry Trends on Sensor Technologies (INTERPHEX 2024)

PharmaTech

Jay Rajagopalan, senior director—Engineering & Product Management for Malema at PSG Biotech, shared insights at on how current industry trends are shaping the development and advancement of sensor technologies.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

PharmaTimes

Both will develop cancer vaccine candidates in selected haematological and solid tumour indications

95
article thumbnail

Q&A: Cell and gene therapy value assessments need a rework to allow access

Pharmaceutical Technology

Paolo Morgese, vice president of European public affairs at the Alliance for Regenerative Medicine, discusses the barriers affecting access to gene therapies.

article thumbnail

New clinical trial aims to investigate skin patches to spot lung transplant rejection

PharmaTimes

Involving 152 patients, the SENTINEL trial aims to cut lung transplant rejection by up to 50%

article thumbnail

How New Regulations Are Impacting Pharmaceutical Manufacturing Facility Design

PharmaTech

New regulations, including those put forth by Annex 1, require many pharmaceutical manufacturers to rethink their facility designs to promote compliance.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Gap in Medicaid Impacts Access to Services for Justice-Involved Patients

Pharmacy Times

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

article thumbnail

The next phase for mRNA: Looking beyond COVID-19

Pharmaceutical Technology

Following the success of the COVID-19 vaccines, there has been an increasing focus on mRNA’s potential to address a wide range of diseases, including cancer.

59
article thumbnail

Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer

Pharmacy Times

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

55
article thumbnail

FDA approves Takeda’s ENTYVIO SC for Crohn’s disease

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy to treat adults with moderately to severely active Crohn's disease (CD).

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A